Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-068513
Filing Date
2025-05-12
Accepted
2025-05-12 06:30:23
Documents
80
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q apge-20250331.htm   iXBRL 10-Q 2224336
2 EX-10.1 apge-ex10_1.htm EX-10.1 428172
3 EX-10.2 apge-ex10_2.htm EX-10.2 73825
4 EX-10.3 apge-ex10_3.htm EX-10.3 31843
5 EX-31.1 apge-ex31_1.htm EX-31.1 18265
6 EX-31.2 apge-ex31_2.htm EX-31.2 18293
7 EX-32.1 apge-ex32_1.htm EX-32.1 13800
  Complete submission text file 0000950170-25-068513.txt   9961721

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT apge-20250331.xsd EX-101.SCH 1236548
82 EXTRACTED XBRL INSTANCE DOCUMENT apge-20250331_htm.xml XML 1723959
Mailing Address 221 CRESCENT ST. BUILDING 17, SUITE 102B WALTHAM MA 02453
Business Address 221 CRESCENT ST. BUILDING 17, SUITE 102B WALTHAM MA 02453 650-394-5230
Apogee Therapeutics, Inc. (Filer) CIK: 0001974640 (see all company filings)

EIN.: 934958665 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41740 | Film No.: 25932494
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)